肝硬化腹水诊治争议问题

谢渭芬; 曾欣

doi:10.3969/j.issn.1001-5256.2014.07.006

肝硬化腹水诊治争议问题

DOI: 10.3969/j.issn.1001-5256.2014.07.006

谢渭芬,
曾欣

上海长征医院消化内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2737
- HTML全文浏览量: 18
- PDF下载量: 812
- 被引次数: 0
出版历程
- 收稿日期: 2014-03-31
- 出版日期: 2014-07-20

Controversial problems in management of cirrhotic ascites

Department of Gastroenterology, Changzheng Hospital, Shanghai

摘要

摘要: 腹水是肝硬化预后不良的重要指标。近年来尽管出台了很多有关肝硬化腹水的指南和共识,但其处理中仍存在一些争议。回顾了目前肝硬化腹水处置中的难点及争议问题,如补钠和限钠的时机、利尿剂的选择、利水剂的应用价值、大量放腹水后补充白蛋白的方案、经颈静脉肝内门体分流术的指征和疗效等;并指出运用循证医学手段解决上述争议性问题,有助于提高肝硬化腹水的诊疗水平,改善患者预后。
- 腹水 /
- 肝硬化 /
- 综述
Abstract: Ascites is an important indicator of poor prognosis of liver cirrhosis. Although several guidelines and consensus statements on the management of ascites have been published in the past years, there are still a lot of controversial problems in this regard. The current controversial problems and difficulties in the management of ascites, such as the timing of sodium supplementation or sodium restriction, the selection of diuretics, the application value of aquaretics, the strategy of albumin administration after large- volume paracentesis, and the indications and efficacy of transjugular intrahepatic portosystemic shunt, are reviewed. It is pointed out that further studies on these problems with evidence- based medicine means will enhance the diagnosis and treatment of cirrhotic ascites and improve patients' prognosis.
- ascites /
- liver cirrhosis /
- review

HTML全文

参考文献(18)

[1]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.

[2]RUNYON BA, AASLD.Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012[J].Hepatology, 2013, 57 (4) :1651-1653.

[3]MOORE KP, WONG F, GINES P, et al.The management of ascites in cirrhosis:report on the consensus conference of the International Ascites Club[J].Hepatology, 2003, 38 (1) :258-266.

[4]REYNOLDS TB, LIEBERMAN FL, GOODMAN AR.Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid[J].Gut, 1978, 19 (6) :549-553.

[5]GAUTHIER A, LEVY VG, QUINTON A, et al.Salt or no salt in the treatment of cirrhotic ascites:a randomised study[J].Gut, 1986, 27 (6) :705-709.

[6]GUEVARA M, CARDENAS A, URIZ J, et al.Prognosis in patients with cirrhosis and ascites[M]//GINS P, ARROYO V, RODS J, et al.Ascites and renal dysfunction in liver disease:pathogenesis, diagnosis and treatment.Malden:BlackwellPublishers, 2005:260-270.

[7]SERSTT, GUSTOT T, RAUTOU PE, et al.Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites[J].J Hepatol, 2012, 57 (2) :274-280.

[8]SANTOS J, PLANAS R, PARDO A, et al.Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis.A randomized comparative study of efficacy and safety[J].J Hepatol, 2003, 39 (2) :187-192.

[9]ANGELI P, FASOLATO S, MAZZA E, et al.Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis:results of an open randomised clinical trial[J].Gut, 2010, 59 (1) :98-104.

[10]BERNARDI M.Optimum use of diuretics in managing ascites in patients with cirrhosis[J].Gut, 2010, 59 (1) :10-11.

[11]WONG F, WATSON H, GERBES A, et al.Satavaptan for the management of ascites in cirrhosis:efficacy and safety across the spectrum of ascites severity[J].Gut, 2012, 61 (1) :108-116.

[12]DAHL E, GLUUD LL, KIMER N, et al.Meta-analysis:the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia[J].Aliment Pharmacol Ther, 2012, 36 (7) :619-626.

[13]TORRES VE, CHAPMAN AB, DEVUYST O, et al.Tolvaptan in patients with autosomal dominant polycystic kidney disease[J].N Engl J Med, 2012, 367 (25) :2407-2418.

[14]GINES A, FERNANDEZ-ESPARRACH G, MONESCILLO A, et al.Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis[J].Gastroenterology, 1996, 111 (4) :1002-1110.

[15]POZZI M, OSCULATI G, BOARI G, et al.Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites[J].Gastroenterology, 1994, 106 (3) :709-719.

[16]CAMPBELL MS, BRENSINGER CM, SANYAL AJ, et al.Quality of life in refractory ascites:transjugular intrahepatic portal-systemic shunting versus medical therapy[J].Hepatology, 2005, 42 (3) :635-640.

[17]SALERNO F, CAMMA C, ENEA M, et al.Transjugular intrahepatic portosystemic shunt for refractory ascites:a meta-analysis of individual patient data[J].Gastroenterology, 2007, 133 (3) :825-834.

[18]MALINCHOC M, KAMATH PS, GORDON FD, et al.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J].Hepatology, 2000, 31 (4) :864-871.

施引文献

资源附件(0)

访问统计